Altimmune to Participate at Two Upcoming Investor Conferences
- None.
- None.
GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- H.C. Wainwright 7th Annual NASH Investor Conference (Virtual Conference)
Tuesday, October 24, 2023
Presentation at 10:00 am Eastern Time
- H. C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
Wednesday, October 25, 2023
Fireside chat at 3:00 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Media Contact:
Danielle Cantey
Evoke Canale
Phone: 619-826-4657
danielle.cantey@evokegroup.com
FAQ
What investor conferences will Altimmune participate in?
When will Altimmune's presentation be at the NASH Investor Conference?
What time will the fireside chat be at the HBV Virtual Conference?
Where can I access the webcast of the sessions?
